<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156997</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2018-0429</org_study_id>
    <secondary_id>1K24HL146838-01</secondary_id>
    <nct_id>NCT04156997</nct_id>
  </id_info>
  <brief_title>Extreme Lipids Repository</brief_title>
  <official_title>Extreme Lipids Repository</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational study to establish a repository of samples from patients
      with extreme lipid phenotypes including but not limited to hyperlipidemia, dyslipidemia,
      hyperlipoproteinemia, extreme low/high HDL levels and deranged lipoprotein metabolism. The
      investigators plan to conduct sophisticated composition and functional analyses as well as
      genetic analysis to better understand the determinants of extreme lipid derangements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be recruited from clinical encounters within the University of Texas (UT)
      Southwestern Medical Center, Parkland Hospital, and overall Texas Health Resources health
      systems by screening the Electronic Medical Record (EMR) for those with lipid labs and values
      that satisfy criteria for extreme values. Identified participants will be recruited to
      provide health information via survey, permission to extract clinical information from the
      EMR, and blood collection for future analyses. Measurements will span direct measurement of
      circulating species, genetic analyses, and analysis of circulating cells. The blood specimens
      will be stored for future studies and collaborations and thus, will constitute a blood-based
      repository. All study procedures are experimental but do not involve an actual intervention.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The study is temporarily suspended due to covid-19 policy.
  </why_stopped>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Biological sample collection for repository</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood samples will be collected for preparation of plasma and serum, extraction of DNA and isolation of circulating cells. Future analysis include genomic, proteomic and metabolomic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Data collection for repository</measure>
    <time_frame>Day 1</time_frame>
    <description>Demographic information, clinical history and lipid related bio-marker information will be collected from participants</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lipoprotein Disorder</condition>
  <arm_group>
    <arm_group_label>Patients with extreme lipid phenotypes</arm_group_label>
    <description>Adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and deranged lipoprotein metabolism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Healthy adult volunteers with normal lipid metabolism will be recruited for the purpose of comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention is involved in this study</intervention_name>
    <description>No intervention is involved in this study</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with extreme lipid phenotypes</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, Serum, DNA, Cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with lipid and metabolism disorders and up to 50 healthy volunteers (age 18 years
        or older) with a normal lipid metabolism.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder
             including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and
             deranged lipoprotein metabolism

        Exclusion Criteria:

          -  Anyone under 18 years of age will be excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Rohatgi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Health Resources</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkland Health Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Ambulatory Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoproteins</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>High Density Lipoproteins</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified demographics, risk factors, clinical history, and research-based measures will be shared with other researchers with appropriate approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available after completed enrollment of any participant. The data will be available for the duration of the registry.</ipd_time_frame>
    <ipd_access_criteria>Researchers may request data from the PI, Dr. Anand Rohatgi. Once approval is given and appropriate regulatory approvals are in place, access may be granted and data shared.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

